ProfileGDS5678 / 1460276_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 77% 76% 78% 77% 77% 77% 76% 77% 76% 80% 76% 76% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3552978
GSM967853U87-EV human glioblastoma xenograft - Control 25.287577
GSM967854U87-EV human glioblastoma xenograft - Control 35.0648776
GSM967855U87-EV human glioblastoma xenograft - Control 45.5114478
GSM967856U87-EV human glioblastoma xenograft - Control 55.219177
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1142277
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1112477
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0523776
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.2775477
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1246876
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6088480
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.189876
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1092776
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.4505579